Allergan eye drug fails to impress on safety, upping pressure ahead of key meeting
Allergan on Tuesday disclosed new safety results for an experimental eye drug, abicipar, but a modest improvement in a key inflammation rate…
Dementia: Amyloid PET scans can improve diagnosis and care
PET scans that can detect changes in the brain relating to Alzheimer’s disease could improve the diagnosis and medical care…
Early pancreatic cancer data give Clovis a new path in PARP market
Early Phase 2 data suggest Clovis Oncology’s targeted cancer drug Rubraca may work as a maintenance therapy for certain pancreatic…
Astellas’ AML therapy bests chemo in Phase 3 study
In a Phase 3 trial, Astellas’ Xospata improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) compared to…
Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1
AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today…
Clinical trial finds therapy to be well-tolerated in patients with aggressive brain tumour
A phase I clinical trial that set out to assess the safety of a new combination therapy for a type…